Rapamycin in patients with chronic renal allograft dysfunction
Authors:
- 1 March 2005
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 19 (2) , 236-242
Abstract
Nephrotoxicity of calcineurin inhibitors (CNI) complicates the management of chronic renal allograft dysfunction. Rapamycin is a promising immunosuppressive agent free of nephrotoxicity. The effect of conversion from CNI to rapamycin in recipients with chronic allograft dysfunction is still unclear. We investigated the effect of rapamycin in patients with chronic allograft dysfunction.We conducted a prospective study on kidney transplant recipients with chronic allograft dysfunction. The patients were under classic CNI, mycophenolate mofetil, and prednisolone triple therapy. They had progressive deterioration of the allograft function. They were converted from CNI to rapamycin directly and observed for 6 months. The CNI serum levels before the conversion were within recommended range. Allograft function, clinical features and adverse effects were evaluated before and after the rapamycin conversion.A total of 16 patients were enrolled. Six of them (37.5%) failed to have a smooth conversion because of deterioration of allograft function and intractable adverse effects. Ten patients (62.5%) went through the 6-month observation period with improved graft function. The average reduction of serum creatinine was 27.7% (p < 0.001) in successful conversion. There were no significant differences on age, gender, lipid profile, sugar control, and rapamycin levels between successful and failed conversion. Anemia and diastolic blood pressure were significantly improved after successful conversion. The failed patients had a longer transplantation period (6.1 +/- 4.1 vs. 11.2 +/- 3.4 yr, p < 0.05). Two of them (12.5%) developed bacteria pneumonia. Self-limited diarrhea developed in three patients (18.8%).We suggested that conversion from CNI to rapamycin was beneficial in some kidney transplant recipients with chronic allograft dysfunction.Keywords
This publication has 13 references indexed in Scilit:
- Reversal of chronic cyclosporine nephrotoxicity after heart transplantation—potential role of mycophenolate mofetilThe Journal of Heart and Lung Transplantation, 2002
- Sirolimus: a comprehensive reviewExpert Opinion on Pharmacotherapy, 2001
- RAD IN DE NOVO RENAL TRANSPLANTATION: COMPARISON OF THREE DOSES ON THE INCIDENCE AND SEVERITY OF ACUTE REJECTION 1Transplantation, 2001
- A CALCINEURIN ANTAGONIST-FREE INDUCTION STRATEGY FOR IMMUNOSUPPRESSION IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS AT RISK FOR DELAYED GRAFT FUNCTION1Transplantation, 2001
- Rapamycin in transplantation: A review of the evidenceKidney International, 2001
- THE CLINICAL IMPACT OF NEPHROTOXICITY IN RENAL TRANSPLANTATIONTransplantation, 2000
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS TREATED WITH SIROLIMUS(RAPAMYCIN)Transplantation, 1998
- Renal function after 10 years' treatment with cyclosporin for psoriasisBritish Journal of Dermatology, 1998
- RAPAMYCIN INHIBITS TRANSPLANT VASCULOPATHY IN LONG-SURVIVING RAT HEART ALLOGRAFTSTransplantation, 1995